Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04440280 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Apr 29, 2026 → Apr 29, 2027
See other at-risk trials from Massachusetts Eye and Ear Infirmary

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Apr 29, 2026 to Apr 29, 2027v9
  2. Site contact updatedv8
  3. Primary completion date: Apr 29, 2025 to Apr 29, 2026
    • Study completion date: Apr 30, 2025 to Apr 30, 2027
    • Site contact updated
    v7
  4. Primary completion date: May 1, 2024 to Apr 29, 2025v6
  5. Site contact updatedv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Aug 1, 2022 to May 1, 2024
    • Study completion date: Dec 30, 2022 to Apr 30, 2025
    v4
  2. Primary completion date: Aug 1, 2021 to Aug 1, 2022
    • Study completion date: Dec 30, 2021 to Dec 30, 2022
    • Start date changed from estimate of Nov 6, 2020 to Sep 16, 2020
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date: Aug 1, 2020 to Nov 6, 2020
    • Enrollment target: 33 to 45
    • Study sites: 0 to 1
    • Eligibility criteria shortened, about 8 words
    • Study description expanded, about 11 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.
Trial Details
NCT Number NCT04440280
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions
(from sponsor)		 Fuchs Endothelial Corneal Dystrophy
Related terms Fuchs' Endothelial Dystrophy
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov